Global Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Immunotherapy) - Industry Forecast 2023-2030

Global Non-Small Cell Lung Cancer Market size was valued at USD 23664.89 million in 2021 and is poised to grow from USD 26948.36 million in 2022 to USD 76334.72 million by 2030, growing at a CAGR of 13.9% in the forecast period (2023-2030).

The global non-small cell lung cancer (NSCLC) market refers to the pharmaceutical and biotechnology industry focused on the diagnosis, treatment, and management of non-small cell lung cancer, which is the most common type of lung cancer. NSCLC accounts for a significant portion of lung cancer cases globally and encompasses various subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The NSCLC market involves the development of targeted therapies, immunotherapies, chemotherapy, and supportive care options to improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The global non-small cell lung cancer market is segmented based on therapy, region. Based on therapy it is categorized into targeted therapy, chemotherapy, and immunotherapy. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.

Driver

Lung cancer, particularly NSCLC, remains a leading cause of cancer-related deaths worldwide. The increasing prevalence and incidence of NSCLC drive the demand for effective diagnostic tools, treatment options, and supportive care measures. Aging populations, tobacco smoking, exposure to environmental pollutants, and lifestyle factors contribute to the rising burden of NSCLC. Precision medicine approaches, such as molecular profiling and genomic testing, have revolutionized the treatment landscape for NSCLC. Targeted therapies that specifically target genetic mutations and alterations in cancer cells have shown promising results in improving patient outcomes. The development of companion diagnostics and personalized treatment strategies fuels the growth of the NSCLC market.

Restraint

NSCLC tumors can develop resistance to targeted therapies and immunotherapies over time. Tumor heterogeneity, the presence of different subclones within a tumor, contributes to treatment resistance and poses challenges in achieving durable responses. Overcoming drug resistance and understanding tumor heterogeneity are ongoing research priorities in the NSCLC market.

Market Trends

The NSCLC market is witnessing a shift towards combination therapies that involve the use of multiple treatment modalities, such as targeted therapies, immunotherapies, and chemotherapy. Combining therapies with different mechanisms of action aims to enhance treatment efficacy, overcome resistance, and improve patient outcomes. Liquid biopsies, which involve the analysis of circulating tumor DNA (ctDNA) and other biomarkers in blood samples, are gaining importance in the diagnosis and monitoring of NSCLC. These non-invasive tests offer the potential for real-time monitoring of tumor mutations and treatment response. Companion diagnostics that identify predictive biomarkers for targeted therapies and immunotherapies continue to play a crucial role in treatment decision-making. The NSCLC market is increasingly focused on patient-centric care, emphasizing the holistic management of patients' physical, emotional